新辅助化疗对乳腺癌TNM分期及术后治疗方案影响的研究

目的通过研究新辅助化疗对乳腺癌根治术后病理分期及治疗方案的影响,进一步评价新辅助化疗的临床价值。方法对100例经空芯针穿刺取材病理确诊的乳腺癌患者,给予临床证实有效的新辅助化疗方案2周期治疗,继之行根治术,术后病理检查并做免疫组化测ER、PR和c-erbB-2,与化疗前的检查结果比对。结果经新辅助化疗后,乳腺癌原发灶明显缩小,11%达到完全缓解(CR);腋窝淋巴结阳性率下降,21.6%达到完全缓解(CR);ER、PR和c-erbB-2结果与新辅助化疗前不相符,不符合率分别为46%、37%和12%。结论新辅助化疗对降低病期、争取保乳机会、筛选敏感的化疗药物有一定作用,但因其影响了术后病理结果,不利于医生制定放疗、内分泌治疗及基因治疗等方案,有待于进一步研究解决此矛盾。

Effect of neoadjuvant chemotherapy on pathological stage and designing of therapy plan for breast cancer

Objective To evaluate the clinical value of neoadjuvant chemotherapy for breast cancer on pathological stage and designing of therapy plan.Methods A total of 100 breast cancer patients had been pathologically confirmed,they received radical operation after 2 cycles of neoadjuvant chemotherapy,We compared the pathological results with those before therapy.Results After neoadjuvant chemotherapy,the primary cancer became smaller,11% of them was completely release(CR);the rate of positive axillary lymph node decreasd,21.6% of them was completely release(CR);ER(46%),PR(37%)and c-erbB-2(12%)were quite different from those before therapy.Conclusion Neoadjuvant chemotherapy may be good for decreasing the clinical stage,earning chance for breast conservation operation and screening sensitive drugs for breast cancer,but it also causes effect on postoperation pathological results,this is no good for doctor to make therapy plan.